Provided by Tiger Trade Technology Pte. Ltd.

Virax Biolabs Group Limited

0.1765
+0.00331.91%
Volume:100.00K
Turnover:17.71K
Market Cap:1.31M
PE:-0.14
High:0.1799
Open:0.1760
Low:0.1733
Close:0.1732
52wk High:1.35
52wk Low:0.1732
Shares:7.42M
Float Shares:6.99M
Volume Ratio:0.98
T/O Rate:1.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2376
EPS(LYR):-1.6248
ROE:-83.82%
ROA:-48.40%
PB:0.25
PE(LYR):-0.11

Loading ...

Virax Biolabs Group Ltd. COO and Director Nigel William McCracken files initial beneficial ownership statement

Reuters
·
Mar 20

Virax Biolabs Delays 2025 Annual Shareholder Meeting After Failing to Reach Quorum, Reschedules for March 18, 2026

Reuters
·
Mar 19

Virax Biolabs Group names director Evan Michael Norton in initial beneficial ownership filing

Reuters
·
Mar 19

Virax Biolabs Director Iain David Miller Files Initial Beneficial Ownership Statement

Reuters
·
Mar 19

Virax Biolabs price target lowered to $1 from $3 at H.C. Wainwright

TIPRANKS
·
Jan 10

Virax Biolabs Raises $5 Million in Private Placement Sale of Shares

Reuters
·
Dec 05, 2025

Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement

THOMSON REUTERS
·
Dec 05, 2025

Press Release: Virax Biolabs Group Limited Announces $5 Million Private Placement

Dow Jones
·
Dec 04, 2025

Crude Oil Gains 1%; Macy's Reports Strong Q3 Results

Benzinga
·
Dec 04, 2025

Virax Biolabs Highlights Clinical Progress and Outlines 2026 Strategic Priorities

Reuters
·
Dec 03, 2025

Virax completes patient recruitment for its clinical study evaluating ViraxImmun

TIPRANKS
·
Nov 03, 2025

Virax Biolabs Group Ltd: Incorporating FDA Recommendations Into Its Ongoing Clinical and Analytical Development Programs

THOMSON REUTERS
·
Nov 03, 2025

Virax Biolabs Group Ltd - Receives FDA Feedback on Viraximmune T Cell Assay

THOMSON REUTERS
·
Nov 03, 2025

Virax Biolabs Completes UK Recruitment for ViraxImmune T Cell Assay Study in Post-Acute Infection Syndromes

Reuters
·
Nov 03, 2025